Last reviewed · How we verify
Apomorphine Nasal Powder
Apomorphine works by stimulating dopamine receptors in the brain, which helps to improve motor function in people with Parkinson's disease.
Apomorphine works by stimulating dopamine receptors in the brain, which helps to improve motor function in people with Parkinson's disease. Used for Treatment of 'off' episodes in advanced Parkinson's disease.
At a glance
| Generic name | Apomorphine Nasal Powder |
|---|---|
| Sponsor | Britannia Pharmaceuticals Ltd. |
| Drug class | Dopamine agonist |
| Target | Dopamine receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
Apomorphine is a dopamine agonist that directly stimulates dopamine receptors in the brain, bypassing the normal dopamine-producing neurons that are damaged in Parkinson's disease. This helps to improve motor function, including tremors, stiffness, and bradykinesia. Apomorphine is typically used as a rescue medication to help manage 'off' episodes in people with advanced Parkinson's disease.
Approved indications
- Treatment of 'off' episodes in advanced Parkinson's disease
Common side effects
- Nausea
- Vomiting
- Dizziness
- Headache
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Apomorphine Nasal Powder CI brief — competitive landscape report
- Apomorphine Nasal Powder updates RSS · CI watch RSS
- Britannia Pharmaceuticals Ltd. portfolio CI